CABA vs. OPK, BEAM, FUSN, SANA, NMRA, VIR, CGEM, BCRX, TARS, and FDMT
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include OPKO Health (OPK), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), Cullinan Therapeutics (CGEM), BioCryst Pharmaceuticals (BCRX), Tarsus Pharmaceuticals (TARS), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "medical" sector.
OPKO Health (NASDAQ:OPK) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
OPKO Health presently has a consensus price target of $3.17, suggesting a potential upside of 131.14%. Cabaletta Bio has a consensus price target of $34.33, suggesting a potential upside of 236.93%. Given OPKO Health's higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than OPKO Health.
OPKO Health has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500.
In the previous week, OPKO Health had 4 more articles in the media than Cabaletta Bio. MarketBeat recorded 8 mentions for OPKO Health and 4 mentions for Cabaletta Bio. OPKO Health's average media sentiment score of 1.02 beat Cabaletta Bio's score of 0.30 indicating that Cabaletta Bio is being referred to more favorably in the news media.
Cabaletta Bio has lower revenue, but higher earnings than OPKO Health. Cabaletta Bio is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.
64.6% of OPKO Health shares are owned by institutional investors. 47.3% of OPKO Health shares are owned by insiders. Comparatively, 9.9% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cabaletta Bio has a net margin of 0.00% compared to Cabaletta Bio's net margin of -31.44%. Cabaletta Bio's return on equity of -17.89% beat OPKO Health's return on equity.
OPKO Health received 421 more outperform votes than Cabaletta Bio when rated by MarketBeat users. However, 70.00% of users gave Cabaletta Bio an outperform vote while only 65.70% of users gave OPKO Health an outperform vote.
Summary
OPKO Health beats Cabaletta Bio on 9 of the 16 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cabaletta Bio Competitors List
Related Companies and Tools
